Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 187


Bayesian model reveals latent atrophy factors with dissociable cognitive trajectories in Alzheimer's disease.

Zhang X, Mormino EC, Sun N, Sperling RA, Sabuncu MR, Yeo BT; Alzheimer’s Disease Neuroimaging Initiative..

Proc Natl Acad Sci U S A. 2016 Oct 4. pii: 201611073.


Defining imaging biomarker cut points for brain aging and Alzheimer's disease.

Jack CR Jr, Wiste HJ, Weigand SD, Therneau TM, Lowe VJ, Knopman DS, Gunter JL, Senjem ML, Jones DT, Kantarci K, Machulda MM, Mielke MM, Roberts RO, Vemuri P, Reyes D, Petersen RC.

Alzheimers Dement. 2016 Sep 30. pii: S1552-5260(16)32875-8. doi: 10.1016/j.jalz.2016.08.005.


Plasma tau in Alzheimer disease.

Mattsson N, Zetterberg H, Janelidze S, Insel PS, Andreasson U, Stomrud E, Palmqvist S, Baker D, Tan Hehir CA, Jeromin A, Hanlon D, Song L, Shaw LM, Trojanowski JQ, Weiner MW, Hansson O, Blennow K; ADNI Investigators..

Neurology. 2016 Sep 30. pii: 10.1212/WNL.0000000000003246.


Morphometricity as a measure of the neuroanatomical signature of a trait.

Sabuncu MR, Ge T, Holmes AJ, Smoller JW, Buckner RL, Fischl B; Alzheimer's Disease Neuroimaging Initiative..

Proc Natl Acad Sci U S A. 2016 Sep 27;113(39):E5749-56. doi: 10.1073/pnas.1604378113.


An investigation of cerebrovascular lesions in dementia with Lewy bodies compared to Alzheimer's disease.

Sarro L, Tosakulwong N, Schwarz CG, Graff-Radford J, Przybelski SA, Lesnick TG, Zuk SM, Reid RI, Raman MR, Boeve BF, Ferman TJ, Knopman DS, Comi G, Filippi M, Murray ME, Parisi JE, Dickson DW, Petersen RC, Jack CR, Kantarci K.

Alzheimers Dement. 2016 Aug 10. pii: S1552-5260(16)32682-6. doi: 10.1016/j.jalz.2016.07.003.


LRRK2 variation and dementia with Lewy bodies.

Heckman MG, Soto-Ortolaza AI, Sanchez Contreras MY, Murray ME, Pedraza O, Diehl NN, Walton R, Labbé C, Lorenzo-Betancor O, Uitti RJ, van Gerpen J, Ertekin-Taner N, Smith GE, Kantarci K, Savica R, Jones DT, Graff-Radford J, Knopman DS, Lowe VJ, Jack CR, Petersen RC, Parisi JE, Rademakers R, Wszolek ZK, Graff-Radford NR, Ferman TJ, Dickson DW, Boeve BF, Ross OA.

Parkinsonism Relat Disord. 2016 Oct;31:98-103. doi: 10.1016/j.parkreldis.2016.07.015.


Arguing against the proposed definition changes of PD.

Boeve BF, Dickson DW, Duda JE, Ferman TJ, Galasko DR, Galvin JE, Goldman JG, Growdon JH, Hurtig HI, Kaufer DI, Kantarci K, Leverenz JB, Lippa CF, Lopez OL, McKeith IG, Singleton AB, Taylor A, Tsuang D, Weintraub D, Zabetian CP.

Mov Disord. 2016 Aug 5. doi: 10.1002/mds.26721. [Epub ahead of print] Review.


Effects of hormone therapy on brain structure: A randomized controlled trial.

Kantarci K, Tosakulwong N, Lesnick TG, Zuk SM, Gunter JL, Gleason CE, Wharton W, Dowling NM, Vemuri P, Senjem ML, Shuster LT, Bailey KR, Rocca WA, Jack CR Jr, Asthana S, Miller VM.

Neurology. 2016 Aug 30;87(9):887-96. doi: 10.1212/WNL.0000000000002970. Epub 2016 Jul 29.


Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrum.

Knopman DS, Jack CR Jr, Lundt ES, Weigand SD, Vemuri P, Lowe VJ, Kantarci K, Gunter JL, Senjem ML, Mielke MM, Machulda MM, Roberts RO, Boeve BF, Jones DT, Petersen RC.

Neurobiol Aging. 2016 Oct;46:32-42. doi: 10.1016/j.neurobiolaging.2016.06.003. Epub 2016 Jun 16.


RAB39B gene mutations are not a common cause of Parkinson's disease or dementia with Lewy bodies.

Hodges K, Brewer SS, Labbé C, Soto-Ortolaza AI, Walton RL, Strongosky AJ, Uitti RJ, van Gerpen JA, Ertekin-Taner N, Kantarci K, Lowe VJ, Parisi JE, Savica R, Graff-Radford J, Jones DT, Knopman DS, Petersen RC, Murray ME, Graff-Radford NR, Ferman TJ, Dickson DW, Wszolek ZK, Boeve BF, Ross OA, Lorenzo-Betancor O.

Neurobiol Aging. 2016 Sep;45:107-8. doi: 10.1016/j.neurobiolaging.2016.03.021. Epub 2016 Mar 24.


TREM2 p.R47H substitution is not associated with dementia with Lewy bodies.

Walton RL, Soto-Ortolaza AI, Murray ME, Lorenzo-Betancor O, Ogaki K, Heckman MG, Rayaprolu S, Rademakers R, Ertekin-Taner N, Uitti RJ, van Gerpen JA, Wszolek ZK, Smith GE, Kantarci K, Lowe VJ, Parisi JE, Jones DT, Savica R, Graff-Radford J, Knopman DS, Petersen RC, Graff-Radford NR, Ferman TJ, Dickson DW, Boeve BF, Ross OA, Labbé C.

Neurol Genet. 2016 Jul 14;2(4):e85. doi: 10.1212/NXG.0000000000000085. eCollection 2016 Aug.


Amyloid-β deposition and regional grey matter atrophy rates in dementia with Lewy bodies.

Sarro L, Senjem ML, Lundt ES, Przybelski SA, Lesnick TG, Graff-Radford J, Boeve BF, Lowe VJ, Ferman TJ, Knopman DS, Comi G, Filippi M, Petersen RC, Jack CR Jr, Kantarci K.

Brain. 2016 Oct;139(Pt 10):2740-2750. Epub 2016 Jul 24.


Age and neurodegeneration imaging biomarkers in persons with Alzheimer disease dementia.

Knopman DS, Jack CR Jr, Wiste HJ, Weigand SD, Vemuri P, Lowe VJ, Kantarci K, Gunter JL, Senjem ML, Mielke MM, Machulda MM, Roberts RO, Boeve BF, Jones DT, Petersen RC.

Neurology. 2016 Aug 16;87(7):691-8. doi: 10.1212/WNL.0000000000002979. Epub 2016 Jul 15.


Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis.

Iturria-Medina Y, Sotero RC, Toussaint PJ, Mateos-Pérez JM, Evans AC; Alzheimer’s Disease Neuroimaging Initiative.

Nat Commun. 2016 Jun 21;7:11934. doi: 10.1038/ncomms11934.


An autoradiographic evaluation of AV-1451 Tau PET in dementia.

Lowe VJ, Curran G, Fang P, Liesinger AM, Josephs KA, Parisi JE, Kantarci K, Boeve BF, Pandey MK, Bruinsma T, Knopman DS, Jones DT, Petrucelli L, Cook CN, Graff-Radford NR, Dickson DW, Petersen RC, Jack CR Jr, Murray ME.

Acta Neuropathol Commun. 2016 Jun 13;4(1):58. doi: 10.1186/s40478-016-0315-6.


MAPT haplotype H1G is associated with increased risk of dementia with Lewy bodies.

Labbé C, Heckman MG, Lorenzo-Betancor O, Soto-Ortolaza AI, Walton RL, Murray ME, Allen M, Uitti RJ, Wszolek ZK, Smith GE, Kantarci K, Knopman DS, Lowe VJ, Jack CR Jr, Ertekin-Taner N, Hassan A, Savica R, Petersen RC, Parisi JE, Maraganore DM, Graff-Radford NR, Ferman TJ, Boeve BF, Dickson DW, Ross OA.

Alzheimers Dement. 2016 Jun 7. pii: S1552-5260(16)30260-6. doi: 10.1016/j.jalz.2016.05.002. [Epub ahead of print]


A semi-mechanism approach based on MRI and proteomics for prediction of conversion from mild cognitive impairment to Alzheimer's disease.

Liu H, Zhou X, Jiang H, He H, Liu X; Alzheimer’s Disease Neuroimaging Initiative.

Sci Rep. 2016 Jun 7;6:26712. doi: 10.1038/srep26712.


Predicting Survival in Dementia With Lewy Bodies With Hippocampal Volumetry.

Graff-Radford J, Lesnick TG, Boeve BF, Przybelski SA, Jones DT, Senjem ML, Gunter JL, Ferman TJ, Knopman DS, Murray ME, Dickson DW, Sarro L, Jack CR Jr, Petersen RC, Kantarci K.

Mov Disord. 2016 Jul;31(7):989-94. doi: 10.1002/mds.26666. Epub 2016 May 23.


MR spectroscopy, APOE genotype, and evolving β-amyloid pathology: What is being detected and when.

Kantarci K, Goldberg TE.

Neurology. 2016 May 10;86(19):1750-1. doi: 10.1212/WNL.0000000000002680. Epub 2016 Apr 15. No abstract available.


Early Postmenopausal Transdermal 17β-Estradiol Therapy and Amyloid-β Deposition.

Kantarci K, Lowe VJ, Lesnick TG, Tosakulwong N, Bailey KR, Fields JA, Shuster LT, Zuk SM, Senjem ML, Mielke MM, Gleason C, Jack CR, Rocca WA, Miller VM.

J Alzheimers Dis. 2016 May 7;53(2):547-56. doi: 10.3233/JAD-160258.

Items per page

Supplemental Content

Loading ...
Support Center